Gregory Oleary, MD
Family Medicine · Gastonia, NCNPI 1306866579
Payments from drug & device makers
Across 124 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$401
- Lilly USA, LLC$201
- Novo Nordisk$195
- Pfizer$151
- Amgen$145
- GSK$145
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,368100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $401 |
| Lilly USA, LLC | 11 | $201 |
| Novo Nordisk | 12 | $195 |
| Pfizer | 9 | $151 |
| Amgen | 9 | $145 |
| GSK | 8 | $145 |
| AstraZeneca | 6 | $103 |
| Merck | 5 | $98 |
| Exact Sciences | 4 | $88 |
| Boston Scientific | 2 | $84 |
| Astellas Pharma US Inc | 3 | $66 |
| Kvk-tech, Inc. | 1 | $64 |
| Boehringer Ingelheim | 3 | $64 |
| Johnson & Johnson | 3 | $51 |
| Tris Pharma Inc | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Abbott | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Bayer | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Abiomed | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
How this compares
$2,368 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $186,303 |
| EliquisApixaban | 92 | $102,906 |
| RybelsusSemaglutide | 30 | $43,041 |
| JardianceEmpagliflozin | 36 | $34,789 |
| MounjaroTirzepatide | 26 | $29,414 |
| JanuviaSitagliptin Phosphate | 33 | $29,395 |
| LinzessLinaclotide | 23 | $24,843 |
| XareltoRivaroxaban | 25 | $22,728 |
| FarxigaDapagliflozin Propanediol | 14 | $17,191 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $15,422 |
| TradjentaLinagliptin | 16 | $12,541 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $11,237 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $10,370 |
| MyrbetriqMirabegron | 18 | $9,630 |
| Bydureon BciseExenatide Microspheres | 12 | $9,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $195 | $229,344196 claims |
| PfizerEliquis | $151 | $102,90692 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $64 | $57,70065 claims |
| MerckJanuvia, Janumet | $98 | $36,08845 claims |
| Lilly USA, LLCMounjaro | $201 | $29,41426 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $103 | $28,31940 claims |
| AbbVieLinzess, Synthroid | $401 | $27,93872 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $145 | $24,57250 claims |
| Johnson & JohnsonXarelto | $51 | $22,72825 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $9,63018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Gastonia
- Steve VacalisGastonia$693K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.